Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).

about

Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).

Item

http://www.wikidata.org/entity/Q38768069

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Autologous stem cell transplan ...... nish lymphoma group (GELTAMO).

@en

type

Item

label

Autologous stem cell transplan ...... nish lymphoma group (GELTAMO).

@en

prefLabel

Autologous stem cell transplan ...... nish lymphoma group (GELTAMO).

@en

P1476

Autologous stem cell transplan ...... anish lymphoma group (GELTAMO)

@en

P2093

A García-Noblejas

http://www.w3.org/2001/XMLSchema#string

A Jiménez-Ubieto

http://www.w3.org/2001/XMLSchema#string

A López

http://www.w3.org/2001/XMLSchema#string

A López-Guillermo

http://www.w3.org/2001/XMLSchema#string

C Albo

http://www.w3.org/2001/XMLSchema#string

C Nicolás

http://www.w3.org/2001/XMLSchema#string

E Conde

http://www.w3.org/2001/XMLSchema#string

E González Barca

http://www.w3.org/2001/XMLSchema#string

G Debén

http://www.w3.org/2001/XMLSchema#string

J Cannata-Ortiz

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.

Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality

Current treatment standards and emerging strategies in mantle cell lymphoma.

P304

1323-1330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-2998-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Norma C. Gutiérrez

Silvana Novelli

Juan-Manuel Sancho

Juan Carlos García-Ruiz

David Martín-García

P577

2017-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28536895

http://www.w3.org/2001/XMLSchema#string